GH Research Q2 2026: $362.7M Cash Runway, FDA Phase 3 Alignment, and Key Patent Wins

summarizeSummary

GH Research posted a $15.1M net loss for Q2 2026, with $362.7M in cash. The FDA confirmed Phase 3 readiness for CMC and device plans, and two completed Phase 1 trials keep the pivotal program on track for a 2026 start.

check_boxKey Events · Earnings and Guidance · GHRS

• Q2 2026 Financial Results

  A net loss of $15.1M ($0.23/share) compared with $9.3M in Q2 2025, driven by higher R&D expenses of $12.4M. Cash, cash equivalents and marketable securities stood at $362.7M as of June 30, 2026.

• FDA Phase 3 Alignment

  The FDA confirmed that CMC and device plans appear Phase 3 ready. Engagement continues on pivotal program design, with initiation targeted for 2026.

• Phase 1 Trial Completions

  Two trials were completed: GH001-HV-106, evaluating clinical pharmacology of the proprietary aerosol device, and GH001-HV-109, an IND-opening U.S. healthy volunteer study. Doses have been selected for the pivotal program.

• Intellectual Property Strengthened

  U.S. Patent No. 12,685,721 was granted (expiry no earlier than 2043) and European Patent No. 3 927 337 was maintained after opposition (expiry no earlier than 2040), covering mebufotenin for MDD and TRD.

auto_awesomeAnalysis · GHRS · Life Sciences

GH Research's Q2 2026 update pairs financial results with meaningful regulatory and clinical milestones. The net loss widened to $15.1M on higher R&D spending, yet the $362.7M cash position provides ample runway well into the pivotal Phase 3 program. FDA confirmation that CMC and device plans are Phase 3 ready, together with the successful completion of two Phase 1 trials, significantly de-risks the pivotal trial initiation targeted for 2026. New U.S. and European patent grants extend IP protection into the 2040s. While the update reinforces the company's transition from Phase 2b to registration studies, the increased loss and ongoing dilution risk from the $200M ATM program remain key considerations.